Ranbaxy Laboratories is expected to finally launch in the US market, the first generic version of Swiss drug maker Novartis' Diovan (Valsartan), for which it enjoys a 180-days exclusive marketing opportunity.
This launch, pending since September 2012, would happen immediately without any delay as it has managed an approval from the US Food and Drug Administration (USFDA). Novartis, which earns about USD 3.4 billion from this drug globally.
Commenting on the same, Sarabjit Kour Nangra, vice president research-pharma, Angel Broking said, "This is one of the key opportunities for the company, however, the main upsides for the stock would from here on would accrue after the merger with Sun Pharmaceuticals, pending which we remain neutral, as of now."
Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.